MENU
+Compare
GMAB
Stock ticker: NASDAQ
AS OF
Aug 15 closing price
Price
$23.31
Change
+$0.31 (+1.35%)
Capitalization
14.08B

GMAB Genmab A/S ADS Forecast, Technical & Fundamental Analysis

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer... Show more

GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for GMAB with price predictions
Aug 15, 2025

GMAB sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for GMAB moved above the 200-day moving average on July 22, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 13, 2025. You may want to consider a long position or call options on GMAB as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GMAB just turned positive on August 14, 2025. Looking at past instances where GMAB's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

GMAB moved above its 50-day moving average on August 12, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GMAB crossed bullishly above the 50-day moving average on July 15, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in of 328 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 216 cases where GMAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for GMAB moved out of overbought territory on July 28, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GMAB broke above its upper Bollinger Band on July 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.704) is normal, around the industry mean (19.407). P/E Ratio (12.058) is within average values for comparable stocks, (50.758). Projected Growth (PEG Ratio) (2.192) is also within normal values, averaging (2.852). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (4.533) is also within normal values, averaging (299.803).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

GMAB is expected to report earnings to fall 18.82% to 43 cents per share on November 06

Genmab A/S ADS GMAB Stock Earnings Reports
Q3'25
Est.
$0.44
Q2'25
Beat
by $0.15
Q1'25
Beat
by $0.09
Q4'24
Beat
by $0.49
Q3'24
Missed
by $0.02
The last earnings report on August 07 showed earnings per share of 54 cents, beating the estimate of 38 cents. With 1.49M shares outstanding, the current market capitalization sits at 14.08B.
A.I. Advisor
published General Information

General Information

an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer and other diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Carl Jacobsens Vej 30
Phone
+45 70202728
Employees
2204
Web
https://www.genmab.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JNUG92.772.65
+2.94%
Direxion Daily Jr Gld Mnrs Bull 2X ETF
TBX28.390.07
+0.25%
ProShares Short 7-10 Year Treasury
MYMJ24.50N/A
N/A
SPDR SSGA My2030 Municipal Bond ETF
SMAY24.58-0.06
-0.26%
FT Vest US Sm Cp Mod Buffr ETF- May
FESM34.24-0.10
-0.29%
Fidelity Enhanced Small Cap ETF

GMAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with TECH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
+1.44%
TECH - GMAB
41%
Loosely correlated
-0.26%
ARVN - GMAB
38%
Loosely correlated
+0.14%
IPSC - GMAB
38%
Loosely correlated
+2.15%
IMTX - GMAB
36%
Loosely correlated
+7.29%
NVO - GMAB
35%
Loosely correlated
+2.87%
More